April 26 (Reuters) - Johnson & Johnson JNJ.N:
JOHNSON & JOHNSON'S TAR-200 MONOTHERAPY DEMONSTRATES HIGHEST COMPLETE RESPONSE RATE WITH SUSTAINED CLINICAL BENEFITS IN PATIENTS WITH CERTAIN TYPES OF BLADDER CANCER
JOHNSON & JOHNSON - PHASE 2B STUDY: 82% ACHIEVE COMPLETE RESPONSE, 52.9% CANCER-FREE AT ONE YEAR
JOHNSON & JOHNSON - TAR-200 POTENTIAL TO TRANSFORM OUTCOMES FOR BCG-UNRESPONSIVE BLADDER CANCER
JOHNSON & JOHNSON - INITIATES FDA APPLICATION FOR TAR-200 UNDER RTOR PROGRAM
Source text: ID:nPn6mRPrna
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。